On Nov 05, major Wall Street analysts update their ratings for $Glaukos (GKOS.US)$, with price targets ranging from $140 to $149.
J.P. Morgan analyst Allen Gong maintains with a buy rating, and adjusts the target price from $130 to $145.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and maintains the target price at $145.
Needham analyst David Saxon maintains with a buy rating, and adjusts the target price from $137 to $149.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $139 to $140.
Piper Sandler analyst Matthew O'Brien maintains with a buy rating, and maintains the target price at $140.
Furthermore, according to the comprehensive report, the opinions of $Glaukos (GKOS.US)$'s main analysts recently are as follows:
Glaukos' Q3 outcomes surpassed consensus forecasts with iDose generating $8.8M in conjunction with a 12.3% increase in the iStent infinite and the broader iStent range within the U.S. market. Additionally, the company's Glaucoma business is expanding steadily, achieving growth of over 20% internationally.
Glaukos' third quarter sales surpassed consensus forecasts, fueled by the performance of iDose and OUS MIGS. Following this, management increased their sales guidance by $5 million at the midpoint, corresponding to the scale of the outperformance. There is positive momentum anticipated for iDose continuing into the fourth quarter and towards 2025.
Here are the latest investment ratings and price targets for $Glaukos (GKOS.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月5日，多家華爾街大行更新了$Glaukos (GKOS.US)$的評級，目標價介於140美元至149美元。
摩根大通分析師Allen Gong維持買入評級，並將目標價從130美元上調至145美元。
富國集團分析師Larry Biegelsen維持買入評級，維持目標價145美元。
Needham分析師David Saxon維持買入評級，並將目標價從137美元上調至149美元。
BTIG分析師Ryan Zimmerman維持買入評級，並將目標價從139美元上調至140美元。
派傑投資分析師Matthew O'Brien維持買入評級，維持目標價140美元。
此外，綜合報道，$Glaukos (GKOS.US)$近期主要分析師觀點如下：
glaukos的第三季度業績超過共識預測，iDose推動下，在美國市場上iStent infinite和更廣泛的iStent區間產生了880萬美元的收入。此外，該公司的青光眼業務穩步擴張，在國際市場上實現了超過20%的增長。
glaukos的第三季度銷售額超過共識預測，受益於iDose和OUS MIGS的表現。隨後，管理層將銷售指導值在中點處提高500萬美元，與業績超越的規模相對應。預計iDose在第四季度持續保持積極勢頭，並朝着2025年繼續發展。
以下爲今日5位分析師對$Glaukos (GKOS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
